샘플 요청 목록

 카트 문의
시장보고서
상품코드
1782823

세계의 간전이 치료 시장

Liver Metastases Treatment
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 370 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

간전이 치료 세계 시장은 2030년까지 47억 달러에 달할 전망

2024년에 34억 달러로 추정되는 간전이 치료 세계 시장은 2024-2030년 분석 기간 동안 CAGR 5.6%로 성장하여 2030년에는 47억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 화학요법은 CAGR 6.0%를 기록하며 분석 기간 종료까지 26억 달러에 달할 것으로 예측됩니다. 표적요법 분야의 성장률은 분석 기간 동안 CAGR 5.0%로 추정됩니다.

미국 시장은 9억 2,460만 달러로 추정, 중국은 CAGR 9.0%로 성장 예측

미국의 간전이 치료 시장은 2024년에 9억 2,460만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 분석 기간인 2024-2030년 CAGR 9.0%를 기록하며 2030년에는 예측 시장 규모 9억 5,370만 달러에 달할 것으로 예측됩니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 2.7%와 5.6%로 예측됩니다. 유럽에서는 독일이 CAGR 3.7%로 성장할 것으로 예측됩니다.

세계의 간전이 치료 시장 - 주요 동향과 촉진요인 정리

간전이에 가장 효과적인 치료법은?

간전이는 다른 원발성 암 부위에서 간으로 전이된 이차적 종양으로, 복잡한 치료적 문제를 야기합니다. 치료법은 종양의 크기, 위치, 환자의 전신 상태에 따라 달라집니다. 전통적으로 전이가 제한적이고 간 기능이 양호한 환자에게는 외과적 절제술이 표준 치료법이었습니다. 간 절제술은 효과적이지만, 전이가 다발성이기 때문에 실행 가능한 환자는 극히 일부에 불과합니다. 수술을 선택할 수 없는 경우, RFA(Radiofrequency Ablation Therapy)나 MWA(Microwave Wound Ablation Therapy)와 같은 대체 접근법이 점점 더 많이 사용되고 있으며, 작은 종양을 열로 파괴하는 최소침습적 솔루션을 제공하고 있습니다. 또한, 경동맥화학색전술(TACE)과 경동맥방사선색전술(TARE)은 전신 독성을 최소화하면서 고용량의 국소 화학요법이나 방사선요법을 간에 직접 투여함으로써, 특히 수술이 불가능한 종양을 가진 환자들에게 큰 호응을 얻고 있습니다. 간전이에 대한 면역요법은 아직 초기 단계이지만, 펨브롤리주맙이나 니볼루맙과 같은 체크포인트 억제제가 일부 환자에서 생존율을 향상시켜 유망한 치료법으로 떠오르고 있습니다. 전신치료, 특히 단클론항체나 티로신 키나아제 억제제와 같은 표적 치료제는 암세포의 증식에 필수적인 분자 경로를 차단함으로써 치료에 혁명을 일으켰습니다. 또한, 정위적 방사선 치료(SBRT)는 특히 희소전이 환자에서 수술 이외의 효과적인 대안으로 떠오르고 있습니다. 유전자 프로파일링을 활용한 맞춤형 의료는 점점 더 많은 치료 옵션을 형성하고 있으며, 종양 전문의는 만능 접근법에 의존하지 않고 종양 생물학에 따라 치료법을 조정할 수 있게 되었습니다. 화학요법, 방사선요법, 분자표적 치료제 등 여러 치료법을 병용하는 병용요법의 발전은 특히 대장암 간전이(CRLM)의 무진행 생존율을 크게 향상시키고 있습니다.

정밀의료의 발전은 간전이 관리를 어떻게 변화시키고 있는가?

정밀의학은 분자진단, 예측 분석, 표적 치료를 통합하여 간전이 치료 상황을 크게 바꾸어 놓았습니다. 혈액 샘플에서 순환 종양 DNA(ctDNA)를 검출하는 액체 생검 기술의 출현은 조기 발견과 실시간 치료 모니터링에 혁명을 일으켰습니다. 액체 생검은 비침습적으로 종양의 진화를 추적하고, 치료 전략을 적시에 조정하고, 내성 메커니즘을 조기에 식별할 수 있게 해줍니다. 종양의 분자 프로파일링은 대장암 전이에 대한 KRAS 및 BRAF 억제제, 유방암 간전이에 대한 HER2 표적 치료제 등 맞춤형 치료법 개발로 이어졌습니다. 인공지능(AI)과 머신러닝 알고리즘은 방대한 데이터세트를 분석하여 특정 치료법에 대한 개별 반응을 예측함으로써 치료 전략을 더욱 정교하게 만들고, 종양학 의사결정에 있어 시행착오를 최소화하고 있습니다. 또한, AI를 활용한 영상 기술은 종양의 시각화와 치료 계획을 강화하여 보다 정확한 방사선 치료 및 중재적 종양학 치료를 가능하게 하고 있습니다. 또 다른 중요한 돌파구는 영상 진단약과 치료제를 결합하여 전이세포를 고도로 표적 공격하는 테라노스틱스의 등장입니다. 루테튬-177과 이트륨-90을 기반으로 한 방사성동위원소 치료는 신경내분비 및 대장 간전이 치료에서 그 효과를 인정받고 있습니다. 또한, 오가노이드를 이용한 조사(환자 유래 종양세포를 실험실 환경에서 배양하여 약물의 효능을 검증하는 것)가 통합되면 정밀 종양학이 더욱 정교해질 수 있습니다. 마이크로새틀라이트 불안정성(MSI) 상태나 종양 돌연변이 부하(TMB)와 같은 예측 바이오마커의 역할 증가도 면역치료의 적용을 형성하는 데 매우 중요한 역할을 하고 있으며, 가장 반응성이 높은 환자군에게만 고가이지만 효과적인 치료법을 제공할 수 있도록 하고 있습니다. 이러한 혁신은 생존율 향상과 치료 관련 독성 감소를 약속하는 고도로 개인화된 데이터 기반 치료 전략으로의 전환을 강조합니다.

최소침습적 치료는 간전이 치료의 미래인가?

간전이 치료에서 최소침습적 치료로의 전환은 종양학에서 가장 결정적인 트렌드 중 하나입니다. 기존의 외과적 절제술은 효과적이지만, 큰 위험, 긴 입원 기간, 높은 합병증 발생률로 인해 보다 최소침습적인 대안에 대한 수요가 증가하고 있습니다. 중재적 방사선학은 경피적 절제술(RFA, Radiofrequency Ablation)이나 마이크로파 소작술(MWA)과 같은 획기적인 치료법의 길을 열었습니다. 냉동절제술은 널리 사용되지는 않지만, 종양세포를 효과적으로 파괴하면서 주변 조직의 완전성을 유지할 수 있기 때문에 널리 보급되고 있습니다. 복강경 수술과 로봇 보조 수술의 보급은 정확도 향상, 절개창의 축소, 회복 시간 단축을 가능하게 하여 이 분야에 또 다른 변화를 가져왔습니다. 화학색전술(TACE), 방사선색전술(TARE) 등의 경동맥 치료는 절제 불가능한 간전이가 있는 환자, 특히 대장암과 간세포암 환자에서 표준 치료법으로 사용되고 있습니다. 로봇 간 절제술을 포함한 로봇 보조 수술의 보급으로 외과의사는 복잡한 수술을 능숙하게 수행하고 환자의 외상을 최소화할 수 있게 되었습니다. 나노기술에 기반한 약물전달 시스템 또한 종양에 직접 화학요법제를 투여할 수 있는 수단을 제공하고, 특이성을 향상시켜 전신 부작용을 줄일 수 있도록 하고 있습니다. 또한, 고밀도집속초음파(HIFU)는 절개나 마취 없이 음파를 이용해 암 조직을 파괴하는 유망한 비침습적 치료법으로 떠오르고 있습니다. 의료 시스템이 환자 중심 치료로 전환하는 가운데, 외래 기반 최소침습 치료에 대한 수요가 증가하면서 전 세계 의료 환경에서 간전이 관리 방식에 패러다임의 전환을 가져올 것으로 예상됩니다.

세계 간전이 치료 시장의 성장을 주도하는 요인은 무엇일까?

간전이 치료 시장의 성장은 표적 치료의 발전, 최소침습적 치료의 채택 증가, 전 세계 암 부담 증가 등 여러 요인에 의해 주도되고 있습니다. 유전자 프로파일링과 바이오마커 기반 치료의 획기적인 발전에 힘입어 정밀의료로의 전환은 치료의 지평을 넓히고, 우수한 임상 결과를 가져오는 개인화된 치료 전략을 가능하게 하고 있습니다. 로봇 보조 수술, AI를 활용한 영상 진단 등 중재적 영상의학 분야의 기술 혁신은 치료 절차를 간소화하고 보다 효과적이고 쉽게 이용할 수 있도록 돕고 있습니다. 간전이의 주요 원인인 대장암, 유방암, 폐암의 유병률 증가는 새로운 치료 옵션에 대한 수요를 증가시키고 있습니다. 또한, 종양학 연구개발, 특히 면역요법 및 병용요법에 대한 투자가 증가하고 있는 것도 시장 확대를 가속화하고 있습니다. 외래 치료 및 최소침습적 치료에 대한 소비자의 선호도가 높아지면서 방사선 소작술(RFA), 경동맥 화학색전술(TACE), 정위적 방사선 치료(SBRT)와 같은 기술의 채택이 증가하여 시장 성장을 더욱 촉진하고 있습니다. 액체 생검과 AI 기반 진단의 도입은 조기 발견을 가능하게 하고, 환자 계층화 및 치료 결과의 개선으로 이어집니다. 또한, 바이오 제약사와의 제휴 및 전략적 파트너십이 급증하면서 혁신을 촉진하고 새로운 간전이 치료제의 상용화를 촉진하고 있습니다. 신흥국 정부의 암 연구 및 첨단 치료 접근성 지원 정책은 시장 확대에 중요한 역할을 하고 있습니다. 비용 효율성과 환자의 삶의 질을 우선시하는 가치 기반 의료 모델로의 전환은 비침습적 표적치료에 대한 수요를 더욱 촉진하고 있습니다. 마지막으로, 차세대 면역요법 및 유전자 편집 기술을 포함한 실험적 치료의 임상시험에 대한 인식과 채택이 증가함에 따라 간전이 치료가 더 효과적일 뿐만 아니라 개별 환자의 요구에 점점 더 부합하는 미래를 암시하고 있습니다.

부문

치료 유형(화학요법, 표적요법, 면역요법), 원발성 암(대장암, 유방암), 유통 채널(병원 약국, 전문 약국)

조사 대상 기업 사례

  • 89bio, Inc.
  • Akero Therapeutics
  • AstraZeneca
  • Bayer AG
  • Biocompatibles UK Ltd.
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Ltd.
  • Delcath Systems, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech(a member of Roche Group)
  • Madrigal Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Plus Therapeutics, Inc.
  • Regeneron Pharmaceuticals
  • SillaJen, Inc.
  • Sirtex Medical Limited

AI 통합

우리는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

Global Industry Analysts는 일반적인 LLM 및 업계 고유의 SLM 쿼리를 따르는 대신 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양의 기업, 제품/서비스, 시장 데이터 등 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측하고 있습니다. 이러한 복잡하고 다면적인 시장 역학은 매출원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예상됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

ksm 25.08.08

Global Liver Metastases Treatment Market to Reach US$4.7 Billion by 2030

The global market for Liver Metastases Treatment estimated at US$3.4 Billion in the year 2024, is expected to reach US$4.7 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 6.0% CAGR and reach US$2.6 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 5.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$924.6 Million While China is Forecast to Grow at 9.0% CAGR

The Liver Metastases Treatment market in the U.S. is estimated at US$924.6 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$953.7 Million by the year 2030 trailing a CAGR of 9.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.7% and 5.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Global Liver Metastases Treatment Market - Key Trends & Drivers Summarized

What Are the Most Effective Treatment Modalities for Liver Metastases?

Liver metastases, secondary tumors that spread to the liver from other primary cancer sites, present a complex therapeutic challenge. Treatment modalities vary depending on tumor size, location, and the patient’s overall health condition. Traditionally, surgical resection has been the gold standard for patients with limited metastases and good liver function. Hepatectomy, though effective, is only feasible for a small percentage of patients due to the multifocal nature of metastases. In cases where surgery is not an option, alternative approaches like radiofrequency ablation (RFA) and microwave ablation (MWA) are increasingly used, offering a minimally invasive solution to target small tumors with thermal destruction. Additionally, transarterial chemoembolization (TACE) and transarterial radioembolization (TARE) have gained traction, particularly for patients with inoperable tumors, by delivering high-dose localized chemotherapy or radiation directly to the liver while minimizing systemic toxicity. Immunotherapy, though still in its early stages for liver metastases, has shown promise, with checkpoint inhibitors like pembrolizumab and nivolumab improving survival rates in select patients. Systemic therapies, particularly targeted treatments like monoclonal antibodies and tyrosine kinase inhibitors, have revolutionized treatment by blocking molecular pathways essential for cancer cell proliferation. Moreover, stereotactic body radiotherapy (SBRT) has emerged as a viable non-surgical option, particularly in patients with oligometastatic disease. Personalized medicine, leveraging genetic profiling, is increasingly shaping treatment selection, allowing oncologists to tailor therapies based on tumor biology rather than relying on a one-size-fits-all approach. The evolution of combination therapies-where multiple modalities such as chemotherapy, radiation, and targeted agents are used in tandem-has significantly improved progression-free survival rates, particularly for colorectal cancer liver metastases (CRLM).

How Are Advancements in Precision Medicine Transforming Liver Metastases Management?

Precision medicine has significantly altered the treatment landscape for liver metastases by integrating molecular diagnostics, predictive analytics, and targeted therapies. The advent of liquid biopsy techniques, which detect circulating tumor DNA (ctDNA) in blood samples, has revolutionized early detection and real-time treatment monitoring. Liquid biopsies allow for non-invasive tracking of tumor evolution, facilitating timely adjustments to therapeutic strategies and enabling the early identification of resistance mechanisms. Molecular profiling of tumors has led to the development of personalized therapies, such as KRAS and BRAF inhibitors for colorectal cancer metastases and HER2-targeted treatments for breast cancer liver metastases. Artificial intelligence (AI) and machine learning algorithms are further refining treatment strategies by analyzing vast datasets to predict individual responses to specific therapies, minimizing trial-and-error approaches in oncologic decision-making. Additionally, AI-driven imaging technologies are enhancing tumor visualization and treatment planning, allowing for more precise radiation and interventional oncology procedures. Another significant breakthrough is the rise of theranostics, where diagnostic imaging agents and therapeutic drugs are combined to deliver a highly targeted attack on metastatic cells. Lutetium-177 and Yttrium-90-based radioisotope therapies are gaining recognition for their efficacy in treating neuroendocrine and colorectal liver metastases. Furthermore, the integration of organoid-based research-where patient-derived tumor cells are grown in lab environments to test drug efficacy-holds the potential to refine precision oncology further. The increasing role of predictive biomarkers, such as microsatellite instability (MSI) status and tumor mutational burden (TMB), has also played a pivotal role in shaping immunotherapy applications, ensuring that only the most responsive patient populations receive these costly but highly effective treatments. These innovations collectively underscore a shift towards highly individualized, data-driven treatment strategies that promise improved survival outcomes and reduced treatment-related toxicity.

Is Minimally Invasive Therapy the Future of Liver Metastases Treatment?

The shift toward minimally invasive procedures in liver metastases treatment has been one of the most defining trends in oncology. Conventional surgical resection, though effective, comes with significant risks, longer hospital stays, and higher complication rates, leading to an increased demand for less invasive options. Interventional radiology has paved the way for breakthroughs like percutaneous ablation techniques-radiofrequency ablation (RFA) and microwave ablation (MWA)-which have demonstrated comparable survival benefits for patients with limited metastases while reducing procedure-related morbidity. Cryoablation, though less widely used, is gaining traction due to its ability to preserve surrounding tissue integrity while effectively destroying tumor cells. The widespread adoption of laparoscopic and robotic-assisted surgery has further revolutionized the field by allowing for enhanced precision, smaller incisions, and quicker recovery times. Transarterial therapies, such as chemoembolization (TACE) and radioembolization (TARE), have become standard-of-care approaches for patients with unresectable liver metastases, particularly in colorectal and hepatocellular carcinoma cases. The growing use of robotic-assisted interventions, including robotic liver resections, has enabled surgeons to perform complex procedures with enhanced dexterity and minimal trauma to the patient. Nanotechnology-based drug delivery systems are also on the horizon, providing a means to administer chemotherapeutic agents directly to tumors with improved specificity, reducing systemic side effects. Moreover, high-intensity focused ultrasound (HIFU) is emerging as a promising non-invasive modality, leveraging sound waves to destroy cancerous tissue without the need for incisions or anesthesia. As healthcare systems continue to shift towards patient-centric care, the demand for outpatient-based, minimally invasive treatments is set to rise, offering a paradigm shift in how liver metastases are managed across global healthcare settings.

What Is Driving Growth in the Global Liver Metastases Treatment Market?

The growth in the liver metastases treatment market is driven by several factors, including advancements in targeted therapy, the increasing adoption of minimally invasive treatments, and a rising global cancer burden. The shift towards precision medicine, fueled by breakthroughs in genetic profiling and biomarker-driven therapies, has expanded the treatment landscape, allowing for personalized therapeutic strategies that yield superior clinical outcomes. Technological innovations in interventional radiology, such as robotic-assisted surgery and AI-powered imaging, are streamlining treatment procedures, making them more effective and accessible. The increasing prevalence of colorectal, breast, and lung cancers-primary contributors to liver metastases-is pushing the demand for novel therapeutic options. Moreover, the rising investment in oncology research and development, particularly in immunotherapy and combination therapies, is accelerating market expansion. Growing consumer preference for outpatient and minimally invasive procedures has led to increased adoption of techniques like radiofrequency ablation (RFA), transarterial chemoembolization (TACE), and stereotactic body radiotherapy (SBRT), further propelling market growth. The introduction of liquid biopsies and AI-driven diagnostics is enabling early detection, leading to improved patient stratification and treatment outcomes. Additionally, the surge in biopharmaceutical collaborations and strategic partnerships is fostering innovation, driving the commercialization of novel liver metastases therapies. Government initiatives supporting cancer research and access to advanced treatments in emerging economies are playing a crucial role in expanding market reach. The shift towards value-based healthcare models, where cost-effectiveness and patient quality of life are prioritized, has further fueled the demand for non-invasive and targeted therapies. Lastly, the growing awareness and adoption of clinical trials for experimental treatments, including next-generation immunotherapies and gene editing technologies, signal a future where liver metastases treatment is not only more effective but also increasingly tailored to individual patient needs.

SCOPE OF STUDY:

The report analyzes the Liver Metastases Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy); Primary Cancer (Colorectal Cancer, Breast Cancer); Distribution Channel (Hospital Pharmacies, Specialty Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • 89bio, Inc.
  • Akero Therapeutics
  • AstraZeneca
  • Bayer AG
  • Biocompatibles UK Ltd.
  • Bristol-Myers Squibb Company
  • Cadila Pharmaceuticals Ltd.
  • Delcath Systems, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Genentech (a member of Roche Group)
  • Madrigal Pharmaceuticals
  • Merck & Co., Inc.
  • Novartis AG
  • Ono Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Plus Therapeutics, Inc.
  • Regeneron Pharmaceuticals
  • SillaJen, Inc.
  • Sirtex Medical Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Liver Metastases Treatment - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Secondary Liver Tumors Throws the Spotlight on Advancements in Liver Metastases Treatment
    • Increasing Use of Precision Oncology and Genomic Profiling Drives Adoption of Targeted Therapy Approaches
    • OEM Innovation in Liver-Directed Therapies Such as TARE and TACE Strengthens Localized Treatment Modalities
    • Expansion of Immunotherapy Combinations Spurs New Pathways for Metastatic Liver Cancer Management
    • Growing Integration of Artificial Intelligence in Imaging and Planning Drives Surgical and Radiological Precision
    • Regulatory Approvals of New Systemic Therapies Accelerate Access to Multiline Treatment Protocols
    • OEM Development of Minimally Invasive Ablation Technologies Enhances Patient Recovery and Hospital Efficiency
    • Rising Use of Hepatic Artery Infusion Chemotherapy (HAIC) in Colorectal Liver Metastases Propels Procedural Uptake
    • Increased Adoption of Multidisciplinary Care Models Strengthens Coordination Across Oncology Specialties
    • OEM Partnerships With Academic Institutions Drive Development of Next-Generation Liver Metastases Treatment Protocols
    • Expansion of Transplant Eligibility Criteria for Selected Liver Metastases Patients Spurs Surgical Innovation
    • Surge in Biomarker-Driven Clinical Trials Generates New Therapeutic Targets in Hepatic Metastatic Cancers
    • OEM Emphasis on Personalized Dosimetry in Radiation Therapy Enhances Tumor Control and Reduces Toxicity
    • Growing Patient Awareness and Earlier Diagnosis Increase Candidate Pools for Curative Liver Interventions
    • Emergence of Radiomics and Predictive Modeling Supports Risk Stratification and Treatment Customization
    • Expansion of Proton Therapy and Stereotactic Techniques Strengthens Non-Invasive Treatment Options
    • Rising Need for Palliative Interventions in Advanced-Stage Patients Spurs Innovation in Comfort-Focused Procedures
    • OEM Investment in Drug-Eluting Beads and Precision Embolic Platforms Enhances Drug Delivery Efficiency
    • Globalization of Clinical Trial Participation Expands Market Access to Novel Liver Metastases Therapies
    • Focus on Real-World Evidence and Post-Market Surveillance Reinforces Long-Term Safety and Efficacy Validation
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Liver Metastases Treatment Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Liver Metastases Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Liver Metastases Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Liver Metastases Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Specialty Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Specialty Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Specialty Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Japan 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 53: China Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: China 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 59: China Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: China Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: China 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Liver Metastases Treatment by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Liver Metastases Treatment by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Europe 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Europe 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 71: Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Europe Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Europe 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: France 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: France 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: France 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Germany 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Germany 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 89: Germany Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Germany Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Germany 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Italy 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Italy 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 98: Italy Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Italy Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Italy 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 101: UK Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: UK 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: UK 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 107: UK Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: UK Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: UK 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 110: Spain Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Spain Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Spain 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 113: Spain Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Spain Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Spain 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 116: Spain Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Spain Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Spain 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 119: Russia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Russia Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Russia 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 122: Russia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Russia Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Russia 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 125: Russia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Russia Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Russia 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 128: Rest of Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Europe Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Rest of Europe 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 131: Rest of Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Europe Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Europe 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Europe 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 137: Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 138: Asia-Pacific Historic Review for Liver Metastases Treatment by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 140: Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Asia-Pacific Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 149: Australia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Australia Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Australia 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 152: Australia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Australia Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Australia 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 155: Australia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Australia Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Australia 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 158: India Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: India Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: India 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 161: India Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: India Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: India 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 164: India Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: India Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: India 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 167: South Korea Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: South Korea Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: South Korea 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 170: South Korea Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: South Korea Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: South Korea 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 173: South Korea Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: South Korea Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: South Korea 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 176: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Rest of Asia-Pacific Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Rest of Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 179: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Rest of Asia-Pacific Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Rest of Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of Asia-Pacific Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 185: Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 186: Latin America Historic Review for Liver Metastases Treatment by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Latin America 15-Year Perspective for Liver Metastases Treatment by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 188: Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Latin America Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Latin America 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 191: Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Latin America Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Latin America 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 194: Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Latin America Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Latin America 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 197: Argentina Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Argentina Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Argentina 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 200: Argentina Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Argentina Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Argentina 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 203: Argentina Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Argentina Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Argentina 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 206: Brazil Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Brazil Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Brazil 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 209: Brazil Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Brazil Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Brazil 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 212: Brazil Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Brazil Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Brazil 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 215: Mexico Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Mexico Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Mexico 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 218: Mexico Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Mexico Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Mexico 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 221: Mexico Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Mexico Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Mexico 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 224: Rest of Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Rest of Latin America Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Rest of Latin America 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 227: Rest of Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Rest of Latin America Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Rest of Latin America 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Rest of Latin America Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Rest of Latin America 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 233: Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 234: Middle East Historic Review for Liver Metastases Treatment by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Middle East 15-Year Perspective for Liver Metastases Treatment by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 236: Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Middle East Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Middle East 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 239: Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Middle East Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Middle East 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 242: Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Middle East Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Middle East 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 245: Iran Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Iran Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Iran 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 248: Iran Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Iran Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Iran 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 251: Iran Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Iran Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Iran 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 254: Israel Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Israel Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Israel 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 257: Israel Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Israel Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Israel 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 260: Israel Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Israel Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Israel 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 263: Saudi Arabia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Saudi Arabia Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Saudi Arabia 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 266: Saudi Arabia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Saudi Arabia Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Saudi Arabia 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Saudi Arabia Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Saudi Arabia 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 272: UAE Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: UAE Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: UAE 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 275: UAE Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: UAE Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: UAE 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 278: UAE Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: UAE Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: UAE 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 281: Rest of Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Rest of Middle East Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Rest of Middle East 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 284: Rest of Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Rest of Middle East Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Rest of Middle East 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Rest of Middle East Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Rest of Middle East 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Liver Metastases Treatment Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 290: Africa Recent Past, Current & Future Analysis for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Africa Historic Review for Liver Metastases Treatment by Treatment Type - Chemotherapy, Targeted Therapy and Immunotherapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Africa 15-Year Perspective for Liver Metastases Treatment by Treatment Type - Percentage Breakdown of Value Sales for Chemotherapy, Targeted Therapy and Immunotherapy for the Years 2015, 2025 & 2030
    • TABLE 293: Africa Recent Past, Current & Future Analysis for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Africa Historic Review for Liver Metastases Treatment by Primary Cancer - Colorectal Cancer and Breast Cancer Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: Africa 15-Year Perspective for Liver Metastases Treatment by Primary Cancer - Percentage Breakdown of Value Sales for Colorectal Cancer and Breast Cancer for the Years 2015, 2025 & 2030
    • TABLE 296: Africa Recent Past, Current & Future Analysis for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Africa Historic Review for Liver Metastases Treatment by Distribution Channel - Hospital Pharmacies and Specialty Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: Africa 15-Year Perspective for Liver Metastases Treatment by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies and Specialty Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제